Deutsche Bank AG Sells 2,665 Shares of Integer Holdings Corporation $ITGR

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Deutsche Bank AG decreased its stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 9.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,716 shares of the medical equipment provider's stock after selling 2,665 shares during the period. Deutsche Bank AG owned approximately 0.08% of Integer worth $3,153,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of ITGR. Sterling Capital Management LLC grew its stake in shares of Integer by 472.9% in the fourth quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 279 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Integer in the fourth quarter worth $354,000. Capital Research Global Investors grew its stake in shares of Integer by 16.0% in the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock worth $186,960,000 after acquiring an additional 194,895 shares during the last quarter. MetLife Investment Management LLC grew its stake in shares of Integer by 4.8% in the fourth quarter. MetLife Investment Management LLC now owns 20,165 shares of the medical equipment provider's stock worth $2,672,000 after acquiring an additional 915 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Integer by 123.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,459 shares of the medical equipment provider's stock worth $591,000 after acquiring an additional 2,465 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.

Integer Price Performance

Shares of NYSE ITGR traded up $3.8190 during midday trading on Friday, reaching $110.6490. 256,433 shares of the company traded hands, compared to its average volume of 373,536. The firm has a market cap of $3.88 billion, a PE ratio of 48.74, a PEG ratio of 0.87 and a beta of 1.02. The stock's 50-day simple moving average is $113.76 and its 200-day simple moving average is $119.04. Integer Holdings Corporation has a 12 month low of $104.93 and a 12 month high of $146.36. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). The company had revenue of $476.00 million for the quarter, compared to the consensus estimate of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. The firm's revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.30 earnings per share. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. As a group, equities analysts anticipate that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Integer news, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director directly owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. This trade represents a 43.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Martin C. Maxwell sold 8,720 shares of Integer stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the transaction, the director directly owned 22,170 shares of the company's stock, valued at $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ITGR shares. Truist Financial decreased their price target on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. Wells Fargo & Company decreased their price target on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Wall Street Zen upgraded shares of Integer from a "sell" rating to a "hold" rating in a research note on Monday, May 19th. Benchmark decreased their price target on shares of Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and lifted their price target for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Integer currently has an average rating of "Buy" and a consensus target price of $140.25.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.